MICAL2 knockdown caused a reduction in viability and loss of motility and invasion in 786-O kidney cancer cells, suggesting that MICAL2 might be a promising target for anti-metastatic therapy (Mariotti et al., 2016). This evidence concerns the gene MICAL2 and kidney cancer.